A new study presented at the 61st European Renal Association Congress has identified high levels of antinephrin autoantibodies in patients with difficult-to-diagnose kidney diseases linked to nephrotic syndrome. This discovery offers a novel biomarker that could revolutionize the diagnosis and management of these diseases. Antinephrin autoantibodies were found in a significant percentage of patients with minimal change disease and focal segmental glomerulosclerosis, as well as in children with idiopathic nephrotic syndrome. The study also showed a correlation between antinephrin autoantibody levels and disease activity, suggesting their potential as a disease progression biomarker. Further research is needed to explore the therapeutic implications of these findings.
Source link
Antinephrin Autoantibodies: Biomarker for Kidney Disease?
